Filters: Keyword is Administration, Oral [Clear All Filters]
Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365(6448):759-61.
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270(1):228-35.
Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. Hypertension. 2010;55(6):1406-11.
Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension. 2010;56(1):62-7.